Annovis Bio (ANVS) announced that the U.S. Food and Drug Administration, FDA, has scheduled a Type C meeting in January 2026 to discuss the Company’s pathway for Parkinson’s disease dementia, PDD. Annovis also reaffirmed that its ongoing Phase 3 AD clinical trial continues to progress with full regulatory alignment on study design, endpoints, and patient population.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
- Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
- Annovis Bio Inc. Reports Q3 2025 Financial Results
- Annovis Bio reports Q3 EPS (37c) vs. (97c) last year
- Annovis Bio sees cash runway to 3Q26